BMS-986301

BMS-986301 is a next-generation small molecule cyclic dinucleotide (CDN) agonist of the stimulator of interferon genes (STING) pathway, developed by Bristol Myers Squibb. It is designed to activate both human and mouse STING variants, leading to immunoactivating and antineoplastic effects. Activation of the STING pathway induces type I interferon responses and enhances anti-tumor immunity by promoting T cell priming and effector function. Preclinical studies have shown that BMS-986301 can induce regression in both injected and non-injected tumors, especially when combined with immune checkpoint inhibitors such as anti–PD-1 or anti–CTLA-4 antibodies. The drug is currently in Phase I clinical trials for advanced solid tumors, including metastatic disease, with ongoing studies evaluating its safety, optimal dosing, administration routes (intratumoral or systemic), and efficacy alone or in combination with other immunotherapies[1][2][3][4][5][6][7][8].

Other names

STING agonist (IFM Therapeutics)IFM-STING agonist